IDEAYA Biosciences, Inc.
IDYA
$17.45
-$0.90-4.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -54.85% | -70.07% | -83.30% | -73.51% | -67.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -54.85% | -70.07% | -83.30% | -73.51% | -67.33% |
| Cost of Revenue | 123.43% | 127.53% | 67.40% | 63.09% | 47.79% |
| Gross Profit | -144.87% | -171.07% | -105.88% | -167.65% | -156.42% |
| SG&A Expenses | 47.57% | 38.84% | 31.22% | 30.02% | 24.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 110.31% | 111.62% | 60.54% | 56.52% | 43.16% |
| Operating Income | -126.39% | -143.23% | -88.94% | -125.77% | -113.47% |
| Income Before Tax | -138.25% | -142.98% | -72.59% | -107.33% | -88.77% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -138.25% | -142.98% | -72.59% | -107.33% | -88.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -138.25% | -142.98% | -72.59% | -107.33% | -88.77% |
| EBIT | -126.39% | -143.23% | -88.94% | -125.77% | -113.47% |
| EBITDA | -128.50% | -145.98% | -90.74% | -129.12% | -116.58% |
| EPS Basic | -79.26% | -67.97% | -19.54% | -50.67% | -31.49% |
| Normalized Basic EPS | -76.90% | -66.50% | -27.69% | -61.26% | -41.74% |
| EPS Diluted | -79.26% | -67.97% | -19.54% | -50.66% | -31.48% |
| Normalized Diluted EPS | -76.90% | -66.50% | -27.69% | -61.19% | -41.68% |
| Average Basic Shares Outstanding | 32.44% | 42.08% | 43.13% | 44.16% | 46.24% |
| Average Diluted Shares Outstanding | 32.44% | 42.08% | 43.13% | 43.56% | 45.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |